| abstract |
The present invention relates to a genetic marker for predicting the prognosis of pancreatic cancer, and to a use thereof, and more particularly, to a genetic marker for predicting the prognosis and diagnosing pancreatic cancer for pancreatic cancer or adjuvant treatment of pancreatic cancer, and a use thereof. The PAC-5 signature, that is, the gene markers of the present invention, that is, LAMA3, E2F7, IFI44, SLC12A2 and LRIG1 genes can be usefully used to predict the prognosis in pancreatic adenocarcinoma patients, as well as diagnose pancreatic cancer. It is expected that it can help predict their prognosis and prolong their survival by selecting patients who can benefit from the implementation of adjuvant therapy after surgery. |